In addition to the isogenic SMARCB1-deficient model, these CBP/p300 dual inhibitors, especially CP-C27, selectively sensitized SMARCB1-deficient cell lines in the cancer cell line panel (Fig. 1k, Supplementary Fig. 1o) to a greater extent than A-485 (Fig. 1l, Supplementary Fig. 1p) and inobrodib (Fig. 1m, Supplementary Fig. 1q). Here, SMARCB1 is linked to cancer.